NCT02514213 - Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 12, 2017

Study Completion Date

December 12, 2017

Conditions

Prostate Cancer

Interventions

BIOLOGICAL

2mg INO-5150 and electroporation device CELLECTRA®-5P

2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P

BIOLOGICAL

8.5mg INO-5150 and electroporation device CELLECTRA®-5P

8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P

BIOLOGICAL

2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P

2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P

BIOLOGICAL

8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P

8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P

DEVICE

Electroporation using CELLECTRA®-5P

Electroporation device CELLECTRA®-5P

Trial Locations (10)

Weill Cornell Medical College, New York

UPMC, Pittsburgh

Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia

Chesapeake Urology Research Associates, Baltimore

University of North Carolina Lineberger Cancer Center, Chapel Hill

Carolina Urologic Research Center, Myrtle Beach

Cleveland Clinic, Cleveland

Karmanos Cancer Institute, Detroit

GU Research Network, LLC/ Urology Cancer Center, Omaha

Seattle Cancer Care Alliance, Seattle